Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1871)	3/27/2003 4:56:53 PM
From: scaram(o)uche	Respond to of 2243

Thanks very much for the follow-up! I stand by my pick. 50-bagger from here would put it at 25% of the GILD capitalization. Three years of cash, if shareholder lawsuits do not eat into it. $4 value if nothing were in the clinic IMO, and a second HCV candidate due to enter trials this year. Market is enormous and not served. Still buying. I'm the ONLY person buying apart from Wellington, but I'm still buying. Convert is assumable in stock-for-stock deal, and company should merge with GILD or TRMS. Criticism of thesis would be VERY much appreciated. Flail away at it, PLEASE.